Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03093116 |
TitleRepotrectinib（TPX-0005）对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究 | 阶段
Phase 1, Phase 2
|
Date Added 2017-03-28 |
地点
California, United States
Colorado, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 澳大利亚 比利时 加拿大 中国 丹麦 法国 德国 香港 Hungary 意大利 日本 大韩民国 荷兰 波兰 新加坡 西班牙 台湾 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
口服雷博替尼（TPX-0005） |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05277051 |
Title对晚期实体瘤患者进行的 GSK4381562 首次人体研究 | 阶段
第 1 阶段
|
Date Added 2022-03-14 |
地点
California, United States
North Carolina, United States Oklahoma, United States Pennsylvania, United States Texas, United States Utah, United States 澳大利亚 加拿大 中国 法国 日本 大韩民国 西班牙 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Dostarlimab, GSK4381562 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04984369 |
TitleHLX208（BRAF V600E 抑制剂）联合西妥昔单抗治疗一线治疗后出现 BRAF V600E 突变的转移性结直肠癌 (mCRC) 的疗效观察 | 阶段
第二阶段
|
Date Added 2021-07-30 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cetuximab Injection [Erbitux], HLX208 |
标签
MSS/ MMRp
|
| NCT ID NCT02465060 |
TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | 阶段
第二阶段
|
Date Added 2015-06-08 |
地点
Alabama, United States
Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States 关岛 波多黎各 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib |
标签
MSS/ MMRp
|
| NCT ID NCT02608385 |
TitleStudy of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2015-11-18 |
地点
Illinois, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT03289962 |
TitleA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | 阶段
第 1 阶段
|
Date Added 2017-09-21 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States 比利时 加拿大 德国 荷兰 西班牙 瑞典 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, Autogene cevumeran, Tecentriq |
标签
MSS/ MMRp
|
| NCT ID NCT04483219 |
TitleTyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. | 阶段
第二阶段
|
Date Added 2020-07-23 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
Unknown status
|
药物
TKI ± anti-PD-1 antibody |
标签
MSS/ MMRp
|
| NCT ID NCT03658785 |
Title治疗晚期实体瘤的免疫疗法 | 阶段
第 1 阶段
|
Date Added 2018-09-05 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine, TIL |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03096093 |
TitleInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2017-03-30 |
地点
英国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
ACIT-1 |
标签
MSS/ MMRp
|
| NCT ID NCT03692429 |
TitlealloSHRINK - 使用基于 NKG2D 的 CYAD-101 嵌合抗原受体 T 细胞的异体 NKG2D 标准 cHemotherapy 方案和免疫疗法 | 阶段
第 1 阶段
|
Date Added 2018-10-02 |
地点
Florida, United States
比利时 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
CYAD-101, FOLFIRI, FOLFOX |
标签
MSI-H/ MMRd, MSS/ MMRp
|
